Carregant...
Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
OBJECTIVES: Hydroxychloroquine (HCQ) 400 mg is approved by the Drug Controller General of India (DCGI) and recommended by the Research Society for the Study of Diabetes in India (RSSDI) clinical practice recommendations 2017 as add-on therapy after metformin and sulfonylurea in Type 2 Diabetes (T2DM...
Guardat en:
| Publicat a: | J ASEAN Fed Endocr Soc |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Journal of the ASEAN Federation of Endocrine Societies
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784185/ https://ncbi.nlm.nih.gov/pubmed/33442141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15605/jafes.034.01.13 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|